89bio

News

Roche has dipped its toe in the M&A water with an agreement to buy US biotech 89bio and its phase 3 candidate pegozafermin for MASH.

News

Positive phase 2b results on liver fibrosis follow similar data with a rival drug from Akero.

News

Merck KGaA has moved to streamline its focus with the sale of its contract development and manufacturing organisation (CDMO) business to Lonza.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.